Skip to main content
VERICI DX PLC logo

VERICI DX PLC — Investor Relations & Filings

Ticker · VRCI ISIN · GB00BM8HZD43 LEI · 213800FI5WE4FVQ3G645 IL Real estate activities
Open in API
Filings indexed 192 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country GB United Kingdom
Listing IL VRCI

About VERICI DX PLC

https://www.vericidx.com/

Verici Dx is an immuno-diagnostics company developing and commercializing a suite of proprietary tests for the kidney transplant market. The company's platform utilizes artificial intelligence-assisted transcriptomic analysis of RNA signatures to provide data-driven insights to clinicians. These tests are designed to decipher the body's immune response and other biological signals, enabling personalized risk assessment for organ injury, rejection, and graft failure. The goal is to assist clinicians in medical management throughout the transplant process, from pre-transplant to late-stage care, ultimately aiming to improve patient outcomes and long-term graft survival.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Regulatory Filings
2026-06-02 English
Study validating economic advantages of PTRA test
Regulatory Filings Classification · 91% confidence The document is a press release published via the London Stock Exchange’s RNS system announcing the publication of a health economics study. It contains no financial statements, no regulatory certifications, no meeting or voting details, and no indication of a specific report attachment or Excel supplement. It is a general corporate/regulatory announcement and does not fit specialized categories such as earnings release, AGM materials, interim report, or M&A filing. Therefore, it falls under the generic “Regulatory Filings” category (RNS).
2026-06-02 English
AMA grants additional CPT® Code for ProtegaTM
Regulatory Filings Classification · 10% confidence The document is a Regulatory News Service (RNS) announcement by Verici Dx plc about receiving an AMA CPT code for their Protega test. It is not a financial report (e.g., Annual Report, Interim Report), earnings release, management change, or any specific corporate action like M&A or share issues. It is a general regulatory/market announcement distributed via the London Stock Exchange’s RNS service, fitting the Regulatory Filings (RNS) category.
2026-06-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 95% confidence The document is a TR-1 Standard form notification of major holdings under the UK’s Disclosure and Transparency Rules (DTR5), indicating a shareholding threshold being crossed (7.817838% by UBS Group AG/UBS AG). It is a regulatory announcement of a change in significant share ownership levels. This matches the “Major Shareholding Notification” category (Code: MRQ).
2026-05-27 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is a TR-1 “Standard form for notification of major holdings,” detailing the crossing of a shareholding threshold, reporting voting rights percentages, dates of threshold crossing and notification, and issuer/holder details. This matches the definition of a Major Shareholding Notification (Code: MRQ).
2026-05-22 English
Clinical study validating PTRA test published
Regulatory Filings Classification · 80% confidence The document is a press release distributed via the London Stock Exchange’s RNS service announcing the publication of a peer-reviewed clinical study by Verici Dx. It does not contain financial statements, voting results, management changes, M&A details, earnings data, or substantive report content but is a general regulatory news announcement. Under the filing definitions, this best fits the fallback category “Regulatory Filings” (RNS).
2026-05-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.